EGFR and non-small cell lung carcinoma: LM is significantly more frequent in NSCLC with epidermal growth factor receptor (EGFR) mutations.[1] Osimertinib is a promising option for NSCLC with LM harboring EGFR mutation regardless of T790M mutational status.[2] However, therapeutic approaches remain a challenge for osimertinib resistant NSCLC patients with LM.